MX2021005088A - Nanoparticulas radioluminiscentes de sesquioxido de lutecio-177 funcionalizadas con peptidos para imagen optica. - Google Patents
Nanoparticulas radioluminiscentes de sesquioxido de lutecio-177 funcionalizadas con peptidos para imagen optica.Info
- Publication number
- MX2021005088A MX2021005088A MX2021005088A MX2021005088A MX2021005088A MX 2021005088 A MX2021005088 A MX 2021005088A MX 2021005088 A MX2021005088 A MX 2021005088A MX 2021005088 A MX2021005088 A MX 2021005088A MX 2021005088 A MX2021005088 A MX 2021005088A
- Authority
- MX
- Mexico
- Prior art keywords
- lutetium
- nanoparticles
- sesquioxide
- sizes
- vivo
- Prior art date
Links
- 239000002105 nanoparticle Substances 0.000 title abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- OHSVLFRHMCKCQY-NJFSPNSNSA-N lutetium-177 Chemical compound [177Lu] OHSVLFRHMCKCQY-NJFSPNSNSA-N 0.000 title 1
- 238000012634 optical imaging Methods 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 229910003443 lutetium oxide Inorganic materials 0.000 abstract 3
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 abstract 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 abstract 2
- 238000001727 in vivo Methods 0.000 abstract 2
- 230000003287 optical effect Effects 0.000 abstract 2
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 239000000084 colloidal system Substances 0.000 abstract 1
- 230000009977 dual effect Effects 0.000 abstract 1
- 238000000295 emission spectrum Methods 0.000 abstract 1
- 125000000524 functional group Chemical group 0.000 abstract 1
- 238000007306 functionalization reaction Methods 0.000 abstract 1
- 239000012216 imaging agent Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000004020 luminiscence type Methods 0.000 abstract 1
- 239000012217 radiopharmaceutical Substances 0.000 abstract 1
- 229940121896 radiopharmaceutical Drugs 0.000 abstract 1
- 230000002799 radiopharmaceutical effect Effects 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
- 238000002371 ultraviolet--visible spectrum Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01F—COMPOUNDS OF THE METALS BERYLLIUM, MAGNESIUM, ALUMINIUM, CALCIUM, STRONTIUM, BARIUM, RADIUM, THORIUM, OR OF THE RARE-EARTH METALS
- C01F17/00—Compounds of rare earth metals
- C01F17/20—Compounds containing only rare earth metals as the metal element
- C01F17/206—Compounds containing only rare earth metals as the metal element oxide or hydroxide being the only anion
- C01F17/224—Oxides or hydroxides of lanthanides
-
- G—PHYSICS
- G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
- G21G—CONVERSION OF CHEMICAL ELEMENTS; RADIOACTIVE SOURCES
- G21G1/00—Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation or particle bombardment, e.g. producing radioactive isotopes
- G21G1/04—Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation or particle bombardment, e.g. producing radioactive isotopes outside nuclear reactors or particle accelerators
- G21G1/06—Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation or particle bombardment, e.g. producing radioactive isotopes outside nuclear reactors or particle accelerators by neutron irradiation
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Materials Engineering (AREA)
- Geology (AREA)
- General Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Crystallography & Structural Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Composite Materials (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- High Energy & Nuclear Physics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Esta invención se refiere un nuevo sistema basado en nanopartículas de sesquióxido de lutecio con alta pureza y cristalinidad de acuerdo con sus planos cristalográficos obtenidos por XDR e indexados acorde a las cartas cristalográficas JCPSD No. 12-0728 (Lu2O3); de morfología cuasiesférica con tamaños de entre 20-45 nm, las cuales después de ser activadas por irradiación neutrónica (177Lu2O3) son radioluminiscentes, presentando espectros de emisión de luminiscencia en la región del infrarrojo cercano, con un máximo de emisión a ~615 nm, lo cual permite la obtención de imágenes ópticas in vivo de su biodistribución. Después de su funcionalización con un péptido inhibidor del antígeno prostático específico de membrana (PSMA), las nanopartículas de sesquióxido de lutecio aumentan sus tamaños a un intervalo de 30-50 nm, presentando bandas de vibración correspondientes a sus grupos funcionales por espectroscopia FT-IR, mismas que se replicaron en las bandas de absorción de los espectros UV-Vis observadas. Además, los valores de potencial zeta en todos los sistemas mantiene un valor absoluto mayor a los 25 mV, lo que implica alta estabilidad del sistema coloidal. El objeto de esta invención es proporcionar un nuevo nanosistema específico (radiofármaco de blancos moleculares) con potencial aplicación en nanomedicina como un agente de imagen dual (óptica y nuclear) in vivo y en la radioterapia de blancos moleculares específicos.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MX2021005088A MX2021005088A (es) | 2021-04-30 | 2021-04-30 | Nanoparticulas radioluminiscentes de sesquioxido de lutecio-177 funcionalizadas con peptidos para imagen optica. |
| PCT/MX2021/050056 WO2022231411A1 (es) | 2021-04-30 | 2021-10-15 | Nanopartículas radioluminiscentes de sesquióxido de lutecio-177 funcionalizadas con péptidos para imagen óptica |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MX2021005088A MX2021005088A (es) | 2021-04-30 | 2021-04-30 | Nanoparticulas radioluminiscentes de sesquioxido de lutecio-177 funcionalizadas con peptidos para imagen optica. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021005088A true MX2021005088A (es) | 2022-11-01 |
Family
ID=83847160
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021005088A MX2021005088A (es) | 2021-04-30 | 2021-04-30 | Nanoparticulas radioluminiscentes de sesquioxido de lutecio-177 funcionalizadas con peptidos para imagen optica. |
Country Status (2)
| Country | Link |
|---|---|
| MX (1) | MX2021005088A (es) |
| WO (1) | WO2022231411A1 (es) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11130675B2 (en) * | 2011-09-02 | 2021-09-28 | The Government Of The United States Of America, As Represented By The Secretary Of The Navy | Flame spray synthesis of nanoparticles of monoclinic Lu203 and dopant |
| US20150240156A1 (en) * | 2012-09-11 | 2015-08-27 | Mingjie Zhou | Lutecium oxide luminescent material and preparation method thereof |
| MX2018003175A (es) * | 2018-03-14 | 2019-09-16 | Instituto Nac De Investigaciones Nucleares | 177lu-dota-hynic-ipsma como un radiofarmaco terapeutico dirigido al antigeno prostatico especifico de membrana. |
-
2021
- 2021-04-30 MX MX2021005088A patent/MX2021005088A/es unknown
- 2021-10-15 WO PCT/MX2021/050056 patent/WO2022231411A1/es active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022231411A1 (es) | 2022-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Licciardello et al. | Biodistribution studies of ultrasmall silicon nanoparticles and carbon dots in experimental rats and tumor mice | |
| Musnier et al. | High photoluminescence of shortwave infrared-emitting anisotropic surface charged gold nanoclusters | |
| TW200726774A (en) | Composition and method for producing stable amyloid beta oligomers | |
| Lee et al. | Non-toxic nanoparticles from phytochemicals: preparation and biomedical application | |
| WO2017209823A3 (en) | Injectable pastes based on oppositely charged polymer/calcium phosphate hybrid nanoparticles | |
| WO2015156870A3 (en) | Biopolymer-mediated assembly of nanoparticles using genetically encoded proteins | |
| MX2021000796A (es) | Composiciones de partículas terapéuticamente activas con superficie modificada por congelación ultra-rápida. | |
| ZA201503004B (en) | Novel mucosal adjuvants and delivery systems | |
| MX2021005088A (es) | Nanoparticulas radioluminiscentes de sesquioxido de lutecio-177 funcionalizadas con peptidos para imagen optica. | |
| NZ759940A (en) | A universal vaccine based on shared tumor neoantigens for prevention and treatment of micro satellite instable (msi) cancers | |
| Zheng et al. | Novel theranostic nanoagent based on CuMo2S3-PEG-Gd for MRI-guided photothermal/photodynamic/chemodynamic therapy | |
| Ren et al. | Gemcitabine induced supramolecular hydrogelations of aldehyde-containing short peptides | |
| CA2743315C (en) | Radioactive gold nanoparticles and methods of making and using them | |
| CN106349575A (zh) | 一种汽车散热器用高低温密封件材料及其制备方法 | |
| WO2016123603A3 (en) | High surface-area lyophilized compositions comprising arsenic for oral administration in patients | |
| Liang et al. | Activatable Mn2+-Armed nanoagonist augments antitumor immunity in colorectal cancer: A NIR-II Photonic neoadjuvant paradigm | |
| CN109432051B (zh) | 一种具有抗卵巢癌活性的靶向纳米粒及制备和应用 | |
| KR20200087722A (ko) | 카르복시메틸-덱스트란 나노 입자를 합성하는 방법 및 이 방법으로 제조된 카르복시메틸-덱스트란 나노 입자 | |
| MX2021004360A (es) | Compuestos de moldeo, conductores. | |
| BR112021006643A8 (pt) | Composições e métodos para aumentar capacidade de distribuição sistêmica, tolerância e eficácia de peptídeos macrocíclicos catiônicos | |
| BR112018068598A2 (pt) | formulações estáveis para liofilização de partículas terapêuticas | |
| Murugan et al. | Correction: Corrigendum: Combinatorial nanocarrier based drug delivery approach for amalgamation of anti-tumor agents in breast cancer cells: an improved nanomedicine strategy | |
| Cudjoe et al. | Correction to “Strong, Rebondable, Dynamic Cross-Linked Cellulose Nanocrystal Polymer Nanocomposite Adhesives” | |
| Sarshough et al. | Particle size and concentration effects on low energy X-ray attenuation in nanostructure and microstructure materials | |
| CN110787294B (zh) | 一种透明质酸-黑色素纳米粒子的制备方法 |